The invention relates to therapeutic agents for use in the prevention or treatment of Alzheimers disease. In particular the invention relates to use of inhibitors of cell cycle reentry and progression to the G1/S transition or inhibitors of progression of the cell cycle through the G1/S transition point in the prevention or treatment of Alzheimers disease.